Fresh analysis indicates that patients who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who halt conventional lifestyle plans.
Research printed in a leading health publication shows that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these medications need to be cognizant of the risk of fast rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to original mass in about 18 months.
Weighing Treatments
The research, which reviewed dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through lifestyle changes alone generally have a more gradual weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts propose the mechanism of the drugs is key to understanding the heightened rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations several times higher than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals say that, due to the significant potential of weight regain, the therapy might need to be long-term.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the chronic nature of obesity," akin to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs report a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly extremely hungry," described one woman.
The struggle is worsened if patients have not developed sustainable dietary or behavioural changes during therapy.
Significant Use
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is higher among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while these medications are effective tools for weight loss, they are not a permanent solution and long-term success hinges on ongoing lifestyle support.
